• LAST PRICE
    0.8351
  • TODAY'S CHANGE (%)
    Trending Up0.0751 (9.8816%)
  • Bid / Lots
    0.8350/ 2
  • Ask / Lots
    0.8351/ 1
  • Open / Previous Close
    0.7700 / 0.7600
  • Day Range
    Low 0.7700
    High 0.8593
  • 52 Week Range
    Low 0.3820
    High 1.4000
  • Volume
    36,703
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 0.76
TimeVolumeVTVT
09:32 ET3500.77
09:55 ET9850.8
10:00 ET2000.8198
10:04 ET8000.8012
10:06 ET1000.8198
10:11 ET50000.8041
10:18 ET10990.802
10:20 ET23000.817999
10:22 ET1000.809
10:40 ET2000.809899
10:45 ET2000.81
10:47 ET2000.8101
10:49 ET1000.8101
10:51 ET64020.8316
11:09 ET10000.84
11:12 ET20030.84
11:16 ET23000.84
11:20 ET20070.8593
11:36 ET10000.855
11:45 ET14740.83
11:48 ET5000.8301
11:54 ET7000.8301
12:08 ET21000.83
12:12 ET2840.83
12:32 ET32000.835
12:42 ET10000.8351
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesVTVT
vTv Therapeutics Inc
79.5M
-2.7x
---
United StatesARMP
Armata Pharmaceuticals Inc
72.7M
-2.0x
---
United StatesVSTM
Verastem Inc
80.9M
-1.0x
---
United StatesCGEN
Compugen Ltd
84.6M
-2.1x
---
United StatesARAV
Aravive Inc
79.0M
-0.6x
---
United StatesBDTX
Black Diamond Therapeutics Inc
79.3M
-0.8x
---
As of 2022-11-28

Company Information

vTv Therapeutics Inc. is a clinical-stage pharmaceutical company that is engaged in the discovery and development of orally administered small molecule drug candidates. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. Its HPP737 is an orally administered, non- central nervous system (CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases. TTP273 is an orally available, small molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which is focused on treating postprandial hyperglycemia in cystic fibrosis related diabetes (CFRD) patients and cystic fibrosis patients. Its products pipeline also includes Nrf2/Bach1 Modulator Program.

Contact Information

Headquarters
3980 Premier Dr, Suite 310HIGH POINT, NC, United States 27265
Phone
336-841-0300
Fax
336-841-0310

Executives

Independent Chairman of the Board
Jonathan Isaacsohn
President, Chief Executive Officer, Director
Paul Sekhri
Executive Vice President, Director
Richard Nelson
Chief Accounting Officer
Barry Brown
Director
Hersh Kozlov

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$79.5M
Revenue (TTM)
$2.0M
Shares Outstanding
104.6M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
-1.24
EPS
$-0.31
Book Value
$-0.11
P/E Ratio
-2.7x
Price/Sales (TTM)
39.4
Price/Cash Flow (TTM)
---
Operating Margin
-1,353.12%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.